Previous 10 | Next 10 |
2023-03-16 20:53:40 ET The following slide deck was published by Geron Corporation in conjunction with their 2022 Q4 earnings call. For further details see: Geron Corporation 2022 Q4 - Results - Earnings Call Presentation
2023-03-16 20:53:05 ET Geron Corporation (GERN) Q4 2022 Earnings Conference Call March 16, 2023 16:30 ET Company Participants Aron Feingold - Vice President, Investor Relations and Corporate Communications John Scarlett - Chairman and Chief Executive Officer Oliv...
2023-03-16 20:00:36 ET Image source: The Motley Fool. Geron (NASDAQ: GERN) Q4 2022 Earnings Call Mar 16, 2023 , 4:30 p.m. ET Operator Continue reading For further details see: Geron (GERN) Q4 2022 Earnings Call Transcript
2023-03-16 16:07:26 ET Geron press release ( NASDAQ: GERN ): Q4 GAAP EPS of -$0.10 beats by $0.03 . Revenue of $0.1M (-90.0% Y/Y) misses by $0.02M . For further details see: Geron GAAP EPS of -$0.10 beats by $0.03, revenue of $0.1M misses by $0.02M
Positive Phase 3 Top-Line Results in Lower Risk MDS Reported in January 2023 Planned 2023 Regulatory Submissions in the U.S. and EU On Track Preparations for Potential Commercial Launch in U.S. Ongoing Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceut...
Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced that it will release its fourth quarter and full-year 2022 financial results after the market closes on Thursday, March 16, 2023 via press release, which will be available on the Company’s we...
Summary Geron recently raised funds, but its stock did not go down. This was because of the excellent IMERGE data. The company is hiring a sales team in anticipation of commercial launch of imetelstat next year. Since my coverage of Geron (GERN) on January 4, the compa...
3 Tips for Finding Short Term Penny Stocks to Buy When it comes to trading penny stocks, many investors focus on the short-term gains that can be achieved through careful selection of stocks that have the potential to increase in value in a short period of time. However, finding the right p...
Geron Corporation (NASDAQ: GERN) and Idexx Laboratories (NASDAQ: IDXX) are both poised to grow and make great long-term healthcare investments, but for different reasons. Geron, a clinical-stage biopharmaceutical company, is about to bring its first product to market, and it...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you’re not investing in healthcare stocks these days, you may be missing out on a huge opportunity. Consider this: We are getting older and living longer as a species. The World Health Organization says that by ...
News, Short Squeeze, Breakout and More Instantly...
RYTELO, for both RS+ and RS- patients, has a Category 1 recommendation for second-line treatment and a Category 2A recommendation for first-line treatment of patients who are ESA ineligible (serum EPO >500 mU/mL) Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that Anil Kapur, Executive Vice President, Corporate Strategy and Chief Commercial Officer, will depart the Company on August 31, 2024, to ...
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company, today announced that it will release its second quarter 2024 financial results and business highlights before the market opens on Thursday, August 8, 2024 via press release, which will be available on the Company ...